Advocating for a world where intellectual
property law serves the public interest.

Access Copyright’s Desperate Declaration of War Against Fair Dealing

[Posted to MichaelGeist.ca, (CC-BY)] Months after the Supreme Court of Canada delivered a stinging defeat to Access Copyright by ruling for an expansive approach to fair dealing and the government passed copyright reforms that further expanded the scope of fair dealing, the copyright collective responded yesterday with what amounts to a desperate declaration of war […]

Cambodian People’s Statement on the EU-India Free Trade Agreement on Generic Drugs

We have been informed about the repeated attempt of the EU to include Intellectual Property Rights provisions that are very likely to undermine the stable supply of affordable life-saving medicines to poorer parts of the world. It is extremely worrisome that, despite assurance made by the Indian government regarding its determination not to include any measures hampering the production and

NSF Survey on Importance of IP to Different Industries, Compared to the USTPO Report on IP in the US Economy

Last year the National Science Foundation published an issue brief by John Jankowski on the importance that American firms in different industries place on intellectual property. It presents survey data showing which industries rely on which types of IP: trade secrets, trademarks, utility patents, design patents, copyrights, or mask works. Firms were asked to rank […]

Open Education Around the World – A 2013 Open Education Week Summary

[Blog post by Creative Commons, (CC-BY)] Creative Commons congratulates all those who participated in the second annual Open Education Week March 11-15, 2013. It’s impressive to see how global open education has become with contributors from over 30 different countries showcasing their work and more than 20,000 people from over 130 countries visiting the Open […]

Debunking Pharma’s Cant Against the Novartis Judgment: Myth and Fact

Novartis, its fellow Big Pharma multinationals, Chambers of Commerce, and PhRMA have all roundly denounced India’s Supreme Court’s decision invalidating Novartis’ patent application for Glivec (Gleevec in the United States) and its affirmation of strict anti-evergreening standards of patentability and inventive step in India. As usual, Big Pharma cannot tell the truth about what India […]

CDT Responds to European Commission Consultation on Intellectual Property enforcement

[Posted on the Center for Democracy and Technology blog by Jens-Henrik Jeppesen (CC-BY-NC)] Last week, CDT submitted its response to the European Commission’s consultation on copyright enforcement. The Commission has previously held public consultations, conferences, and ‘stakeholder dialogues’ on this issue, and the present consultation was structured as a ‘technical survey’ to gather specific information on […]